CA3149390A1 - Virus-like particle vaccines - Google Patents

Virus-like particle vaccines Download PDF

Info

Publication number
CA3149390A1
CA3149390A1 CA3149390A CA3149390A CA3149390A1 CA 3149390 A1 CA3149390 A1 CA 3149390A1 CA 3149390 A CA3149390 A CA 3149390A CA 3149390 A CA3149390 A CA 3149390A CA 3149390 A1 CA3149390 A1 CA 3149390A1
Authority
CA
Canada
Prior art keywords
vlp
virus
vaccine
protein
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3149390A
Other languages
English (en)
French (fr)
Inventor
Daniel R. Henderson
Thomas J. Ellison
George C. TALBOTT
Yeonju SONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verndari Inc
Original Assignee
Verndari Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verndari Inc filed Critical Verndari Inc
Publication of CA3149390A1 publication Critical patent/CA3149390A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3149390A 2019-07-30 2020-07-30 Virus-like particle vaccines Pending CA3149390A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962880547P 2019-07-30 2019-07-30
US62/880,547 2019-07-30
US202062990318P 2020-03-16 2020-03-16
US62/990,318 2020-03-16
PCT/US2020/044196 WO2021022008A1 (en) 2019-07-30 2020-07-30 Virus-like particle vaccines

Publications (1)

Publication Number Publication Date
CA3149390A1 true CA3149390A1 (en) 2021-02-04

Family

ID=74228282

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3149390A Pending CA3149390A1 (en) 2019-07-30 2020-07-30 Virus-like particle vaccines

Country Status (7)

Country Link
US (2) US20220280633A1 (enExample)
EP (1) EP4004036A4 (enExample)
JP (1) JP2022543046A (enExample)
CN (1) CN114729030A (enExample)
AU (1) AU2020321021A1 (enExample)
CA (1) CA3149390A1 (enExample)
WO (1) WO2021022008A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112760420A (zh) * 2021-02-05 2021-05-07 中国科学院长春应用化学研究所 一种用于检测新冠病毒SARS-CoV-2的引物、探针和试剂盒
CN114656529A (zh) * 2021-02-08 2022-06-24 暨南大学 一种新型冠状病毒t细胞的抗原表位肽及其应用
CN115572714A (zh) * 2021-06-21 2023-01-06 江苏泽凯生物医药技术有限公司 一种快速检测SARS-CoV-2病毒中和抗体有效性的方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
US12630831B2 (en) 2019-09-29 2026-05-19 Technion Research & Development Foundation Limited Synthetic non-coding RNAS
US20230314432A1 (en) * 2020-07-10 2023-10-05 Covid Diagnostics Ltd. Compositions, methods, and systems for detecting immune response
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
CN114957409A (zh) * 2021-02-26 2022-08-30 中国科学院上海巴斯德研究所 基于s蛋白r815位点的冠状病毒干预的方法和产品
WO2022187424A1 (en) * 2021-03-04 2022-09-09 Helix Nanotechnologies, Inc. Compositions including sbi adjuvants and methods of use thereof
WO2022191742A1 (en) * 2021-03-11 2022-09-15 Dukhovlinov Ilya Vladimirovich A method for assessment of the cellular immune
AU2022273065A1 (en) * 2021-05-13 2023-11-23 Benevira Inc. Methods and compositions for treatment of viral infection
WO2022261355A1 (en) * 2021-06-09 2022-12-15 Chimeron Bio Corporation Self-amplifying rna-based vlp vaccines
US20250082236A1 (en) * 2021-07-19 2025-03-13 Carnegie Mellon University Scalable Manufacturing of Microneedle Arrays Using Automated High-Throughput Manufacturing Systems and High-Capacity Molding
WO2023023597A1 (en) * 2021-08-18 2023-02-23 Nanored Llc Virus-like particle
MX2024002259A (es) * 2021-09-09 2024-03-06 Univ Basel Acido nucleico producido biologicamente para la produccion de vacunas.
WO2023043933A1 (en) * 2021-09-15 2023-03-23 Verndari, Inc. Stabilized lipid nanoparticle mrna compositions and uses thereof
WO2023062651A1 (en) * 2021-10-13 2023-04-20 Padmanabh Patil Harshad Virus-like particles for respiratory syncytial virus and method of preparation thereof
RU2769224C1 (ru) * 2021-12-30 2022-03-29 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Рекомбинантные вирусоподобные частицы для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2
WO2023167868A2 (en) * 2022-03-01 2023-09-07 Icahn School Of Medicine At Mount Sinai Immunogenic compositions comprising a recombinant neuraminidase and cpg oligonucleotide adjuvant, and uses thereof
KR20260032590A (ko) * 2023-06-29 2026-03-09 세퀴러스 인코포레이티드 재조합 바이러스 유사 입자
WO2025235418A1 (en) * 2024-05-05 2025-11-13 National Health Research Institutes Virus-like particle, preparation method thereof, and use thereof in preparing vaccine
WO2025264980A1 (en) * 2024-06-21 2025-12-26 Georgia Tech Research Corporation Ambient stabilization of mrna-hybrid lipid nanocapsules in sugar glass

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148876A (en) * 1975-09-29 1979-04-10 Burroughs Wellcome Co. Biological preparations
ATE489969T1 (de) * 2002-06-20 2010-12-15 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
WO2008103276A2 (en) * 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
WO2011002522A2 (en) * 2009-07-02 2011-01-06 Medimmune, Llc Methods of making and using synthetic viruses
US20130259928A1 (en) * 2010-09-30 2013-10-03 Franvax S.R.L. Generation of virosome particles
PL2811981T3 (pl) * 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
US10829543B2 (en) * 2012-10-29 2020-11-10 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
CN107073105B (zh) * 2014-09-12 2021-04-06 巴斯特威尔控股有限公司 用于提供含佐剂病毒体的方法及由此可获得的含佐剂病毒体
WO2016039620A2 (en) * 2014-09-12 2016-03-17 Bestewil Holding B.V. Respiratory syncytial virus virosomes
WO2017046801A1 (en) * 2015-09-17 2017-03-23 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112760420A (zh) * 2021-02-05 2021-05-07 中国科学院长春应用化学研究所 一种用于检测新冠病毒SARS-CoV-2的引物、探针和试剂盒
CN112760420B (zh) * 2021-02-05 2023-05-26 中国科学院长春应用化学研究所 一种用于检测新冠病毒SARS-CoV-2的引物、探针和试剂盒
CN114656529A (zh) * 2021-02-08 2022-06-24 暨南大学 一种新型冠状病毒t细胞的抗原表位肽及其应用
CN114656529B (zh) * 2021-02-08 2024-05-31 暨南大学 一种新型冠状病毒t细胞的抗原表位肽及其应用
CN115572714A (zh) * 2021-06-21 2023-01-06 江苏泽凯生物医药技术有限公司 一种快速检测SARS-CoV-2病毒中和抗体有效性的方法

Also Published As

Publication number Publication date
WO2021022008A1 (en) 2021-02-04
EP4004036A4 (en) 2023-11-15
AU2020321021A1 (en) 2022-03-10
EP4004036A1 (en) 2022-06-01
CN114729030A (zh) 2022-07-08
US20230000974A1 (en) 2023-01-05
JP2022543046A (ja) 2022-10-07
US20220280633A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
US20230000974A1 (en) Virus-like particle vaccines
AU2007345768B2 (en) Chimeric influenza virus-like particles
Soema et al. Current and next generation influenza vaccines: Formulation and production strategies
Nian et al. Development of nasal vaccines and the associated challenges
EP2758038B1 (en) Novel influenza hemagglutinin protein-based vaccines
JP5714799B2 (ja) 機能的インフルエンザウイルス様粒子（ｖｌｐ）
US9889189B2 (en) Universal influenza vaccine based on heterologous multiple M2E proteins
US10130700B2 (en) Polyvalent influenza virus-like particles (VLPS) and use as vaccines
US20110262483A1 (en) Methods for isolating enveloped virus-based vlps free of infectious agents
US20120052082A1 (en) Cross-protective influenza vaccine
CN101678096A (zh) 水包油乳液流感疫苗
Sia et al. Engineered nanoparticle applications for recombinant influenza vaccines
WO1998046262A1 (en) Anti-influenza compositions supplemented with neuraminidase
Quan et al. Progress in the development of virus-like particle vaccines against respiratory viruses
Wang et al. Virus‐Like Particles Containing the Tetrameric Ectodomain of Influenza Matrix Protein 2 and Flagellin Induce Heterosubtypic Protection in Mice
Prabakaran et al. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice
US20100086584A1 (en) VACCINE COMPOSITIONS OF M2e, HA0 AND BM2 MULTIPLE ANTIGENIC PEPTIDES
Wu et al. Nanovaccines to combat virus‐related diseases
HK40079920A (en) Virus-like particle vaccines
Li et al. Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity. Vaccines 2021, 9, 75

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240725

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260116

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260130

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260316

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE

Effective date: 20260330

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260703